43
Participants
Start Date
March 31, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
semaglutide
Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
placebo
Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
Microgyn®
Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Novo Nordisk Investigational Site, Neuss
Lead Sponsor
Novo Nordisk A/S
INDUSTRY